TLDR:
- HepaRegeniX, a German company, raised €15M in Series C funding for their regenerative therapy for liver diseases.
- The funding was led by Vesalius Biocapital IV with participation from existing investors.
HepaRegeniX, a clinical stage company based in Tuebingen, Germany, has successfully raised €15M in Series C funding. The round was led by Vesalius Biocapital IV, with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds (HTGF). Fabienne Roussel, Partner at Vesalius Biocapital, will be joining the Non-Executive Board of Directors, while Elias Papatheodorou will take over as the Chief Executive Officer, moving from the Chair of the Board.
The company plans to use the funds to advance the clinical development of its clinical candidate HRX-215. This candidate is a result of the company’s discovery and development of several drug candidates for the treatment of acute and chronic liver diseases. These candidates are based on a novel proprietary molecular target, Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4), with HRX-215 already completing Phase 1 clinical testing.
MKK4 is a key regulator of liver regeneration, and the suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers. This innovative approach holds promise for the treatment of liver diseases. With the new funding secured, HepaRegeniX is poised to further their research and development efforts towards addressing these challenging conditions.
